« Return to News | Ethics/Regulatory

European Commission launches framework for research and innovation

Thursday, December 1, 2011 01:12 PM

EFPIA, the voice of the research-based pharmaceutical industry in Europe, welcomes the launch of the European Commission’s new Framework for Research and Innovation: Horizon 2020.

“The European Commission should be commended for their intention to further develop public-private partnerships (PPP). There is shared understanding that private companies and public bodies must collaborate more and to think about new business models which allow us to work much more quickly to meet unmet needs," said Richard Bergström, director general of EFPIA.

He added: “EFPIA confirms industry interest in continuing public private collaborations which will enable game changing biopharmaceutical research projects that address scientific and technological bottlenecks in areas with grand societal challenges, such as antimicrobial resistance. Such PPPs in life sciences will clearly contribute to the three cornerstones of the Commission proposal: excellent science, industrial leadership and tackling societal challenges.”

Horizon 2020 will be the EU’s funding instrument to implement the Innovation Union. This framework is part of the European Commission’s proposed European Union budget for the period 2014 to 2020. Horizon 2020 is designed to last until the end of this decade.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.